- SCOPUS
- 6507378333
- ORCID
-
0000-0001-5280-8341
- SCOPUS
- 6507851192
- ORCID
-
0000-0002-2171-1085
- SCOPUS
- 6701860897
- SCOPUS
- 35585493200
- ORCID
-
0000-0002-9847-4137
- GND
- 1199377422
- ORCID
-
0000-0002-1964-803X
- SCOPUS
- 6701789254
- SCOPUS
- 6603602989
- SCOPUS
- 58998437700
- ORCID
-
0000-0003-2908-8213
- Other
- corresponding author
- SCOPUS
- 56144795900
- ORCID
-
0000-0001-5719-2187
- GND
- 137638221
- ORCID
-
0000-0002-9315-4863
- ResearcherID
- F-8620-2014
- SCOPUS
- 35269855400
- SCOPUS
- 58076374700
- Other
- connected with university
- GND
- 130286222
- ORCID
-
0009-0002-4975-5386
- SCOPUS
- 60001412000
- SCOPUS
- 7004237276
- Other
- connected with university
Abstract in English:
The main aim of this work was to evaluate the effect of doxorubicin in complex with C₆₀ fullerene (C₆₀ + Dox) on the growth and metastasis of Lewis lung carcinoma in mice and to perform a primary screening of the potential mechanisms of C₆₀ + Dox complex action. We found that volume of tumor from mice treated with the C₆₀ + Dox complex was 1.4 times less than that in control untreated animals. The number of metastatic foci in lungs of animals treated with C₆₀ + Dox complex was two times less than that in control untreated animals. Western blot analysis of tumor lysates revealed a significant decrease in the level of heat-shock protein 70 in animals treated with C₆₀ + Dox complex. Moreover, the treatment of tumor-bearing mice was accompanied by the increase of cytotoxic activity of immune cells. Thus, the potential mechanisms of antitumor effect of C₆₀ + Dox complex include both its direct action on tumor cells by inducing cell death and increasing of stress sensitivity and an immunomodulating effect. The obtained results provide a scientific basis for further application of C₆₀ + Dox nanocomplexes as treatment agents in cancer chemotherapy.